Related Experiment Video
Updated: Jun 8, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Targeted therapies in soft tissue sarcomas
1Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, UK. ian.judson@icr.ac.uk
Abstract:
Soft tissue sarcomas are rare cancers but because of their association with characteristic chromosomal translocations and activating mutations they may be particularly susceptible to molecularly targeted therapies. Gastrointestinal stromal tumour (GIST) became the paradigm for targeted therapy in solid tumours owing to the success of imatinib, which has transformed the prognosis in this disease. Translocation-driven tumours have proved harder to target, but the impact of fusion proteins on gene expression is beginning to be understood and may also reveal new targets for therapy, such as insulin-like growth factor 1 receptor, now that effective inhibitors have been discovered. Angiogenesis inhibition also appears to be a promising area for research in sarcomas and many new targets are emerging at the same time as agents capable of investigating them in the clinic are being developed. It is not unrealistic to hope that targeted therapies will play an increasing role in the management of sarcomas in the near future.
Insights
Molecularly targeted therapies show promise for rare soft tissue sarcomas. Research is advancing to identify new targets and treatments for these challenging cancers, offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Soft tissue sarcomas are rare malignancies.
- Characteristic chromosomal translocations and activating mutations suggest susceptibility to targeted therapies.
- Gastrointestinal stromal tumour (GIST) treatment with imatinib serves as a paradigm for targeted therapy success.
Purpose of the Study:
- To explore the potential of molecularly targeted therapies in managing soft tissue sarcomas.
- To identify emerging therapeutic targets and agents for sarcoma treatment.
- To discuss the evolving role of targeted therapies in sarcoma management.
Main Methods:
- Review of current research on molecular alterations in soft tissue sarcomas.
- Analysis of the impact of fusion proteins on gene expression in translocation-driven tumors.
- Investigation of emerging therapeutic strategies including angiogenesis inhibition.
Main Results:
- Gastrointestinal stromal tumour (GIST) exemplifies successful targeted therapy.
- Understanding fusion protein impact reveals potential new targets like insulin-like growth factor 1 receptor.
- Development of novel agents targeting angiogenesis shows promise.
Conclusions:
- Molecularly targeted therapies are increasingly relevant for soft tissue sarcomas.
- Further research into fusion proteins and angiogenesis inhibition is warranted.
- Targeted therapies are expected to play a significant role in future sarcoma management.
More Related Videos
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...